Ligand Pharmaceuticals Articles

Ligand acquires financial rights to over 15 development programs from Selexis

1 May 2013

Ligand to earn up to $50 million in deal with Spectrum for Captisol-enabled melphalan

14 March 2013

FDA accepts NDA filings from Pfizer/Ligand and Actelion; Bayer submits Alpharadin

16 December 2012

Ligand licenses DARA Program to Retrophin

21 February 2012

Ligand in deal with Chiva for global rights to Fablyn

12 October 2011

Ligand in commercial supply deal with Merck & Co for Captisol

21 June 2011

Ligand acquires CyDex Pharma for upfront $31 million; expects to be profitable this year

28 January 2011

Ligand could earn $100 million in deal with Chiva Pharma for China

7 January 2011

Pfizer/Ligand’s lasofoxifene reduces breast cancer risk in postmenopausal osteoporotic women

8 November 2010

Japan’s health regulator approves GlaxoSmithKline’s Revolade and Xyzal

3 November 2010

Pfizer rolls out osteoporosis drug bazedoxifene in Japan

14 October 2010

Ligand buys milestone and royalty interest in mid-stage AstraZeneca IL-9 program for asthma

24 May 2010

Human Genome/GlaxoSmithKline lupus drug Benlysta disappoints in Ph III; Updates on Seattle Genetics and Ligand milestones

21 April 2010

Showing 1-13 of 13 articles

Go to beginningPrevious
  • 1
NextGo to end